Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.

Therapeutic drug monitoring - 1 Dec 2010

Barry Arden, Levine Marc

Abstract excerpt

Tacrolimus is a commonly used immunosuppressive agent in renal transplantation. Therapeutic drug monitoring of tacrolimus is recommended because it demonstrates wide pharmacokinetic interpatient variability. Part of that variability may be the result of metabolism by cytochrome P450 3A5 (CYP3A5), which is only expressed in some adult individuals. The expression of CYP3A5 has been linked to the CYP3A5 genotype, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Biological Availability
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Metabolic Clearance Rate

Share to Tacrolimus

Source

Identifiers

PMID: 20864901
DOI: 10.1097/FTD.0b013e3181f3c063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.PMID 20864901Read ↗

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentSemantic proximity Read ↗

CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.Semantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry.Semantic proximity Read ↗

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.Semantic proximity Read ↗

CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.Semantic proximity Read ↗

A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics.Semantic proximity Read ↗

Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Pharmacokinetics and Renal Allograft Rejection in Kidney Transplant Recipients: A Meta-Analysis Across Ethnic PopulationsSemantic proximity Read ↗

Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patientsSemantic proximity Read ↗

Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.